An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CareDx, Inc. (Nasdaq: CDNA) will report financial results for the first quarter of 2024, focusing on healthcare solutions for transplant patients. The conference call will take place on May 9, 2024, providing insights for investors and interested parties.
CareDx, Inc. (Nasdaq: CDNA) comunicherà i risultati finanziari per il primo trimestre del 2024, concentrandosi sulle soluzioni sanitarie per i pazienti trapiantati. La conferenza telefonica si terrà il 9 maggio 2024, fornendo spunti per gli investitori e le parti interessate.
CareDx, Inc. (Nasdaq: CDNA) informará sobre los resultados financieros del primer trimestre de 2024, enfocándose en soluciones de atención médica para pacientes trasplantados. La llamada de conferencia se realizará el 9 de mayo de 2024, proporcionando perspectivas para inversores y partes interesadas.
CareDx, Inc. (나스닥: CDNA)는 2024년 1분기 재무 결과를 발표할 예정이며, 이는 이식 환자를 위한 건강 관리 솔루션에 중점을 둘 것입니다. 2024년 5월 9일에 열리는 전화 회의를 통해 투자자 및 관심 있는 당사자들에게 통찰력을 제공할 예정입니다.
CareDx, Inc. (Nasdaq : CDNA) communiquera les résultats financiers du premier trimestre de 2024, en mettant l'accent sur les solutions de santé pour les patients transplantés. La conférence téléphonique aura lieu le 9 mai 2024, offrant des perspectives pour les investisseurs et les parties intéressées.
CareDx, Inc. (Nasdaq: CDNA) wird die Finanzergebnisse für das erste Quartal 2024 bekannt geben, wobei der Fokus auf Gesundheitslösungen für Transplantationspatienten liegt. Die Telefonkonferenz findet am 9. Mai 2024 statt und wird Einblicke für Investoren und interessierte Parteien bieten.
Positive
None.
Negative
None.
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Individuals interested in listening to the conference call may do so by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
When will CareDx report financial results for the first quarter of 2024?
CareDx will report financial results for the first quarter of 2024 after market close on Thursday, May 9, 2024.
What is the stock symbol of CareDx?
The stock symbol of CareDx is CDNA.
How can individuals listen to the conference call by CareDx management?
Individuals can listen to the conference call by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers and referencing Conference ID: CareDx. A live webcast is also available on CareDx's investor relations website at investors.caredxinc.com.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
